Policy

Grace Science does not currently offer an expanded access program.  While Grace Science is committed to making GS-100 broadly accessible to the NGLY1 Deficiency patient population, our first priority is safety.  As we believe this critical objective is best achieved through clinical trials that are well regulated and monitored, access to GS-100 is currently possible only through participation in our clinical trial.